Exemestane steroidal aromatase inhibitor

Oral exemestane 25 mg/day for 2–3 years of adjuvant therapy was generally more effective than 5 years of continuous adjuvant tamoxifen in the treatment of postmenopausal women with early-stage estrogen receptor-positive/unknown receptor status breast in a large well-designed [ citation needed ] trial. Preliminary data from the open-label TEAM trial comparing exemestane with tamoxifen indicated in 2009 that exemestane 25 mg/day is also effective in the primary adjuvant treatment of early-stage breast cancer in postmenopausal women. [17]

Drugs like exemestane and other steroidal aromatase inhibitors have a steroidal structure that competes with the natural aromatase substrate androstenedione . [11] The inhibitor must share important structural features with the endogenous substrate, and as features of the androgens , allowing them to interact with the catalytic site on the enzyme protein. This renders the steroidal aromatase inhibitors inherently selective. [13] Due to its selective inhibition it will not affect the production of the other steroids in the estrogen biosynthetic pathway. [9]

Exemestane steroidal aromatase inhibitor

exemestane steroidal aromatase inhibitor

Media:

exemestane steroidal aromatase inhibitorexemestane steroidal aromatase inhibitorexemestane steroidal aromatase inhibitorexemestane steroidal aromatase inhibitorexemestane steroidal aromatase inhibitor

http://buy-steroids.org